Cargando…
Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment
Although CEBPA double-mutated (CEBPA(DM)) acute myeloid leukemia is considered to be a favorable-risk disease, relapse remains a major cause of treatment failure. Most CEBPA(DM) patients have a classic biallelic mutant combination with an N-terminal mutation leading to production of p30 protein plus...
Autores principales: | El-Sharkawi, Dima, Sproul, Duncan, Allen, Christopher G., Feber, Andrew, Wright, Melissa, Hills, Robert K., Linch, David C., Gale, Rosemary E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777194/ https://www.ncbi.nlm.nih.gov/pubmed/29025912 http://dx.doi.org/10.3324/haematol.2017.173096 |
Ejemplares similares
-
The value of molecular stratification for CEBPA
(DM) and NPM1
(MUT)
FLT3
(WT) genotypes in older patients with acute myeloid leukaemia
por: Dickson, Glenda J., et al.
Publicado: (2015) -
Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia
por: Adamo, Assunta, et al.
Publicado: (2022) -
Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
por: Braun, Theodore P., et al.
Publicado: (2019) -
The ASXL1-G643Wvariant accelerates the development of CEBPA mutant acute myeloid leukemia
por: D’Altri, Teresa, et al.
Publicado: (2020) -
Germline CEBPA mutation in familial acute myeloid leukemia
por: Boada, Matilde, et al.
Publicado: (2021)